Skip to main content
. 2016 Apr 1;48(4):1408–1419. doi: 10.4143/crt.2015.347

Fig. 2.

Fig. 2.

Although all five young patients experienced relapse/progression and died from disease progression, four of the eight older patients remained event free at a median follow-up period of 64 months (range, 39 to 108 months) from diagnosis. For all patients, the 5-year event-free survival (EFS) and overall survival (OS) rates were 38.5±13.5% and 34.6±14.4%, respectively.